Lipella Pharmaceuticals, Inc.

As of June 9, 2025, the technical trend has shifted to mildly bearish, with dominant bearish indicators across daily moving averages, Bollinger Bands, and Dow Theory, despite some mildly bullish signals on the weekly MACD and KST.

Lipella Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $1 million as of March 2025, with a market cap of $12.08 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -125.78%.

As of Jun 18, Lipella Pharmaceuticals, Inc. has a market capitalization of 12.08 million, with net sales of 0.52 million and a net profit of -5.13 million over the last four quarters. As of Dec'24, shareholder's funds were 1.92 million and total assets were 2.67 million.